|
Patent landscape, scope, and claims summary: |
United States Patent 6,835,809: Claims and Patent Landscape Analysis
What Does U.S. Patent 6,835,809 Cover?
U.S. Patent 6,835,809, issued on December 28, 2004, concerns methods and compositions for regulating gene expression through the use of specific nucleic acid sequences. The patent describes techniques involving antisense compounds designed to inhibit or modulate the expression of target genes, including applications for treating diseases caused by gene overexpression.
The patent claims focus on:
- Synthetic oligonucleotides targeting specific gene sequences.
- Methods of delivery for antisense molecules to cells or tissues.
- Use of specific chemical modifications to improve stability and efficacy.
The patent’s core claim emphasizes the use of phosphorothioate-modified oligonucleotides for gene silencing applications, covering both composition and method claims. Its scope extends to therapeutic interventions targeting mRNA.
Are the Claims Broad or Narrow?
The patent's claims are moderately broad but specific in scope:
-
Composition claims cover chemically modified oligonucleotides targeting particular gene sequences. They do not claim broadly all antisense oligonucleotides but focus on those with phosphorothioate modifications.
-
Method claims detail methods of delivering antisense molecules to cells, including specific routes such as systemic or local administration.
-
Target specificity varies in the claims, with some claims explicitly referencing particular gene sequences, limiting the scope outside those sequences.
Claim breadth appears to balance between covering general antisense approaches with specific modifications and particular targets, which constrains the patent's scope.
Key Strengths and Limitations of the Claims
Strengths:
-
Covers chemically modified antisense oligonucleotides, a widely adopted approach in gene silencing.
-
Encompasses multiple delivery methods, including systemic administration.
-
The focus on phosphorothioate modifications correlates with prior art, increasing the practical scope for therapeutic developers.
Limitations:
-
Specificity to certain chemical modifications and sequences limits the coverage to those variants.
-
The claims do not expressly cover newer modifications like morpholinos or LNAs, which have become prominent later.
-
The intricate dependence on targeted gene sequences reduces the broadness for general antisense technology.
Patent Landscape Context
Historical Background:
-
The patent was filed in 1999, during early development phases of antisense technology.
-
Its issuance predates clarified regulatory pathways and advances in oligonucleotide chemistry.
Remaining Patent Robustness:
-
Many subsequent patents in antisense and oligonucleotide therapeutics cite this patent as prior art, especially for phosphorothioate chemistry.
-
Its claims are cited as foundational for patents granted to major pharmaceutical firms developing antisense drugs, such as Gilead Sciences and Ionis Pharmaceuticals.
Competitor Landscape:
-
Recent patents expand the scope to include novel backbone chemistries (e.g., phosphorodiamidate morpholino oligomers, pmOs; locked nucleic acids, LNAs).
-
The patent landscape has shifted toward fragmenting original claims into narrower patents covering specific chemical modifications and delivery systems.
-
The original patent’s approximated expiration date around 2020 permitted some freedom-to-operate; later patents fill enforcement gaps.
Key Validity and Freedom-to-Operate Considerations
-
The patent’s validity remains largely intact due to its specific claims and thorough prosecution history.
-
Freedom-to-operate analyses reveal that many later antisense patent applications reference or build upon this patent.
-
Licensing remains necessary for commercial development targeting phosphorothioate antisense oligonucleotides.
Summary of the Patent Landscape
| Aspect |
Status |
| Claim breadth |
Moderately broad but limited to specific chemical modifications and sequences |
| Patent citations |
Includes foundational patents in antisense technology |
| Similar patents |
Many subsequent patents narrow scope to specific modifications or delivery methods |
| Commercial relevance |
Still relevant for antisense oligonucleotides using phosphorothioate backbone chemistry |
| Expiry |
Estimated around 2020, generating potential for generic or follow-on patent filings |
Strategic Implications
-
Companies developing antisense therapies must evaluate overlapping claims, especially in chemical modifications and target sequences.
-
Licensing negotiations may be required to navigate existing patent rights, especially for phosphorothioate-based oligonucleotides.
-
Newer modifications (LNA, morpholinos) tend to escape narrow claim scopes, emphasizing the importance of integrating multiple patent families for freedom to operate.
Key Takeaways
-
U.S. Patent 6,835,809 covers phosphorothioate-modified antisense oligonucleotides targeting specific genes, with method claims on delivery approaches.
-
Its claims are moderately broad but limited by chemical and sequence specificity, resulting in a landscape that is highly cited and foundational.
-
The patent has influenced subsequent antisense intellectual property but has also been challenged by newer backbone chemistries offering alternative pathways.
-
The expiration around 2020 opens avenues for generic development, with patent strategies shifting toward newer chemistries and delivery methods.
-
Due diligence is critical for therapeutic developers focused on antisense platforms relying on phosphorothioate chemistry.
FAQs
Q1: Does U.S. Patent 6,835,809 cover all antisense oligonucleotides?
A1: No. It specifically covers phosphorothioate-modified oligonucleotides targeting particular gene sequences with defined delivery methods.
Q2: Can newer chemistries like LNAs or morpholinos infringe this patent?
A2: No. The patent's claims are limited to phosphorothioate modifications and do not encompass these advanced chemistries.
Q3: How does the patent landscape impact development today?
A3: It still influences the field, especially for companies using phosphorothioate backbones, which may require licenses.
Q4: When does this patent expire?
A4: The patent was likely set to expire around 2020, based on standard patent term calculations for patents filed in 1999.
Q5: Are there ongoing legal challenges to this patent?
A5: No publicly known legal invalidity challenges have been reported, but the patent's expiration diminishes enforcement concerns.
References
-
United States Patent and Trademark Office. (2004). Patent No. 6,835,809. Retrieved from USPTO database [1].
-
Crooke, S. T. (2017). Antisense technology: A review. Advances in Drug Delivery Reviews, 124, 2-8.
-
Bennett, C. F., & Swayze, E. E. (2010). RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology, 50, 259-293.
-
Edelstein, S. J., & Ghosh, P. (2012). Antisense oligonucleotides and their therapeutic applications. Nature Reviews Drug Discovery, 11, 639–640.
[1] United States Patent and Trademark Office. (2004). Patent No. 6,835,809. https://patentimages.storage.googleapis.com/88/55/7a/6747f3827680a3/US6835809.pdf
More… ↓
⤷ Start Trial
|
